PMC:7252096 / 67779-68122 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T271","span":{"begin":157,"end":165},"obj":"Disease"}],"attributes":[{"id":"A271","pred":"mondo_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1210","span":{"begin":51,"end":56},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1211","span":{"begin":72,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T70149","span":{"begin":107,"end":121},"obj":"Chemical"},{"id":"T98979","span":{"begin":111,"end":121},"obj":"Chemical"}],"attributes":[{"id":"A96986","pred":"chebi_id","subj":"T70149","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A35331","pred":"chebi_id","subj":"T98979","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T438","span":{"begin":0,"end":343},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1980","span":{"begin":57,"end":61},"obj":"Gene"},{"id":"1981","span":{"begin":107,"end":110},"obj":"Gene"},{"id":"1995","span":{"begin":51,"end":56},"obj":"Species"},{"id":"1996","span":{"begin":126,"end":134},"obj":"Species"},{"id":"2003","span":{"begin":157,"end":165},"obj":"Disease"}],"attributes":[{"id":"A1980","pred":"tao:has_database_id","subj":"1980","obj":"Gene:59272"},{"id":"A1981","pred":"tao:has_database_id","subj":"1981","obj":"Gene:1636"},{"id":"A1995","pred":"tao:has_database_id","subj":"1995","obj":"Tax:9606"},{"id":"A1996","pred":"tao:has_database_id","subj":"1996","obj":"Tax:9606"},{"id":"A2003","pred":"tao:has_database_id","subj":"2003","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}

{"project":"2_test","denotations":[{"id":"32413319-15194496-20790540","span":{"begin":288,"end":292},"obj":"15194496"}],"text":"For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of “ACE inhibitors” in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004, Monteil et al., 2020, Vaduganathan et al., 2020)."}